Tagomics exists to make early cancer detection accessible through simple, accurate blood tests, ultimately improving patient survival and quality of life.
Tagomics is building a next-generation disease profiling platform that integrates genetic and epigenetic data into a single, high-throughput workflow - dramatically reducing costs and complexity. By overcoming the limitations of current biochemistry methods, Tagomics enables simpler, more accurate diagnoses that can benefit millions of patients.
Based in Cambridge, the company is already collaborating with many of the world's leading pharmaceutical and diagnostic companies.
